Anti-SARS-CoV-2 Antibody Products

Last Updated: February 11, 2021

Summary Recommendations
Summary Recommendations
There are insufficient data for the COVID-19 Treatment Guidelines Panel (the Panel) to recommend either for or against the use of the following products for the treatment of COVID-19: COVID-19 convalescent plasma The Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the use of convalescent plasma for hospitalized patients with COVID-19 (see Convalescent Plasma for more details). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulins There are currently insufficient data for the Panel to recommend either for or against the use of the following anti-SARS-CoV-2 monoclonal antibodies for the treatment of nonhospitalized patients with mild to moderate COVID-19: Bamlanivimab The combination of casirivimab plus imdevimab The FDA has issued EUAs for the use of bamlanivimab and the casirivimab plus imdevimab combination for nonhospitalized patients with mild to moderate COVID-19 who are at high risk of disease progression (see Anti-SARS-CoV-2 Monoclonal Antibodies for more details). The FDA also recently issued an EUA for bamlanivimab plus etesevimab for the treatment of certain nonhospitalized patients with mild to moderate COVID-19; the Panel will issue recommendations on the use of this combination shortly.
Rating of Recommendations: A = Strong; B = Moderate; C = Optional Rating of Evidence: I = One or more randomized trials without major limitations; IIa = Other randomized trials or subgroup analyses of randomized trials; IIb = Nonrandomized trials or observational cohort studies; III = Expert opinion